<DOC>
	<DOC>NCT00113529</DOC>
	<brief_summary>To assess the maximum tolerated dose and overall safety and tolerability of sunitinib [SU011248] administered in combination with gefitinib (Iressa) for the treatment of patients with metastatic renal cell carcinoma (Phase 1). To assess antitumor activity of the combination of gefitinib and sunitinib (Phase 2).</brief_summary>
	<brief_title>Study Of SU011248 Plus Gefitinib (Iressa) In Patients With Advanced Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Histologically confirmed renal cell carcinoma with metastases Evidence of unidimensionally measurable disease Failure of 1 prior immunotherapy or no prior systemic therapy for metastatic RCC RCC without any clear (conventional) cell component History of or known brain metastases Uncontrolled hypertension or other significant cardiac events within the 12 months prior to study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
</DOC>